Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91989 | 0.90 | GAA (0.58) | GAANPC1TAAR1ALDH1A1HSP90AA1 | |
| SCHEMBL383766 | 0.87 | GAA (0.54) | GAANPC1TAAR1ALDH1A1HSP90AA1 | |
| SCHEMBL12706044 | 0.87 | GAA (0.43) | GAANPC1TAAR1ALDH1A1HSP90AA1 | |
| Chloroneb SCHEMBL22739 | 0.87 | GAA (0.64) | GAANPC1TAAR1ALDH1A1HSP90AA1 | |
| SCHEMBL3754009 | 0.85 | GLA (0.52) | GAANPC1TAAR1ALDH1A1MAPT | |
| SCHEMBL1755249 | 0.85 | NPC1 (0.58) | GAANPC1TAAR1ALDH1A1HSP90AA1 | |
| SCHEMBL92053 | 0.85 | KMT2A (0.47) | GAANPC1TAAR1ALDH1A1MAPT | |
| SCHEMBL5633315 | 0.85 | GAA (0.39) | GAANPC1TAAR1ALDH1A1HSP90AA1 | |
| SCHEMBL2954181 | 0.84 | TAAR1 (0.56) | GAATAAR1ALDH1A1MAPTGLA | |
| SCHEMBL29587813 | 0.82 | GLA (0.53) | GAANPC1TAAR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-9169182-B2 | Chrysophaentin analogs that inhibit FtsZ protein | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169182-B2 | Chrysophaentin analogs that inhibit FtsZ protein | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-27 | — | — | US | disclosed |
| US-20130331460-A1 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130331460-A1 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2146230-B1 | Binary diketopyrrolopyrrole pigment compound for use in colour filters | CLARIANT FINANCE BVI LTD (VG) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012116254-A2 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-08-30 | — | — | WO | disclosed |
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| EP-2145926-B1 | PR 254 pigment preparation for use in colour filters | CLARIANT FINANCE BVI LTD (VG) | 2012-05-30 | — | — | EP | disclosed |
| US-8128848-B2 | Diketopyrrolopyrrole pigment composition for use in color filters | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-03-06 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-4975463-A | VIRICIDES; AIDS TREATMENT | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1990-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CDK1, CDKN1A, CDKL1 | GAA 4060/4885NPC1 3001/4885TAAR1 1547/4885 |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | GAA 1264/4885NPC1 2770/4885TAAR1 2746/4885 |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | GAA 3064/4885NPC1 4182/4885TAAR1 2970/4885 |
| US-20130331460-A1 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | CDC42, CEP170, FNTA | GAA 1566/4885NPC1 2324/4885TAAR1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.